China Pharma Holdings Inc

CPHIHealthcare·Drug Manufacturers - Specialty & Generic·China·Nano·AMEX·Nov 11 • 3:54 PM ET

0.5431-0.0079 (-1.43%)

2026-11-12 05:07 CET

Market cap

23.37 USD m

Revenue, TTM

3.91 USD m

Net income, TTM

-4.47 USD m

Free cash flow, TTM

-0.17 USD m

EPS diluted, TTM

-0.42

P/E

Compare

Price

CPHI against its 20, 50 and 200-day averages

2050200

97.2% under the 52-week high of 19.19 on 21 Jul 2026. 52-week low 0.38 on 12 May 2026. Last 15 sessions, 40.0% high to low

Volume 0.06× normal · the line is the 50-bar volume average

Profile

CPHI

52-week range, 1% of the way up

0.3819.19

China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm's product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.

Employees	221
IPO	Apr 17, 2002
Beta	0.96
ATR, 14d	0.08
Rel volume	0.06
Short float	0.22%
Insider own	6.23%
Inst own	0.51%

Snapshot

6 groups

Valuation

Index	-
Market Cap	23.37M
Enterprise Value	26.97M
Income	-4.47M
Sales	3.91M
Book/sh	0.90
Cash/sh	0.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	221
IPO	Apr 17, 2002

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	5.98
P/B	0.61
P/C	75.39
P/FCF	-
EV/EBITDA	-
EV/Sales	6.90
Quick Ratio	0.08
Current Ratio	0.26
Debt/Eq	0.11
LT Debt/Eq	0.00
Option/Short	No / Yes

Earnings

EPS (ttm)	-0.42
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	73.01% 53.14%
Sales past 3/5Y	-20.03% -17.53%
EPS Y/Y TTM	71.83%
Sales Y/Y TTM	-10.97%
EPS Q/Q	77.78%
Sales Q/Q	-7.55%
Earnings	-
EPS/Sales Surpr.	- -

Ownership

Insider Own	6.23%
Insider Trans	0.00%
Inst Own	0.51%
Inst Trans	304.39%
ROA	-15.21%
ROE	-20.81%
ROIC	-12.28%
Gross Margin	-47.35%
Oper. Margin	-111.84%
Profit Margin	-114.33%
SMA20	-13.80%
SMA50	-22.67%
SMA200	-32.53%
Trades	-

Technical

Shs Outstand	40.52M
Shs Float	40.34M
Short Float	0.22%
Short Ratio	0.05
Short Interest	0.09M
52W High	19.19 -97.17%
52W Low	0.38 42.25%
Volatility	10.51% 9.05%
ATR (14)	0.08
RSI (14)	36.22
Beta	0.96
Rel Volume	0.06
Avg Volume	1.81M
Volume	115,130

Performance

Perf Week	-7.56%
Perf Month	-27.72%
Perf Quarter	-50.17%
Perf Half Y	-45.49%
Perf YTD	-55.12%
Perf Year	-65.30%
Perf 3Y	-87.84%
Perf 5Y	-99.83%
Perf 10Y	-99.55%
Recom	-
Target Price	-
Prev Close	0.55
Price	0.54
Change %	-1.43%

Analyst ratings

latest 1 of 1

Date	Action	Analyst	Rating change	Target	Implied
Jan 08, 2010	Initiated	RRodman & Renshaw	Mkt Outperform	$6	+1,004.8%

Date

Action

Analyst

Rating change

Target

Implied

Jan 08, 2010

Initiated

RRodman & Renshaw

Mkt Outperform

+1,004.8%

Peers

Mkt cap

Ticker	Company	Mkt cap
UPC	Universe Pharmaceuticals INC	7.89M
BGM	BGM Group Ltd	107.50M
SXTC	China SXT Pharmaceuticals Inc	1.95M
ZYBT	Zhengye Biotechnology Holding Ltd	45.19M
HCM	HUTCHMED (China) Limited ADR	2.63B
RDY	Dr. Reddy's Laboratories Ltd ADR	12.36B
AMPH	Amphastar Pharmaceuticals Inc	1.22B
TEVA	Teva- Pharmaceutical Industries Ltd	50.45B
YI	111 Inc ADR	15.21M
POM	Pomdoctor Ltd	13.84M

Ticker

Company

Mkt cap

UPC

Universe Pharmaceuticals INC

7.89M

BGM

BGM Group Ltd

107.50M

SXTC

China SXT Pharmaceuticals Inc

1.95M

ZYBT

Zhengye Biotechnology Holding Ltd

45.19M

HCM

HUTCHMED (China) Limited ADR

2.63B

RDY

Dr. Reddy's Laboratories Ltd ADR

12.36B

AMPH

Amphastar Pharmaceuticals Inc

1.22B

TEVA

Teva- Pharmaceutical Industries Ltd

50.45B

111 Inc ADR

15.21M

POM

Pomdoctor Ltd

13.84M

News

latest 14 of 200

Jul-23-26 06:49PMChina Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering (PR Newswire) +8.19% -17.84%
Jul-22-26 09:25AMChina Pharma Announces Pricing of $5 Million Registered Direct Offering (PR Newswire) -78.89%
Jul-21-26 04:00PMChina Pharma Holdings, Inc. Comments on Unusual Market Activity (PR Newswire) +790.11%
Jul-15-26 12:12PMChina Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity (PR Newswire) +78.92%
May-14-26 08:56AMChina Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity (PR Newswire) +24.45%
Apr-04-25 04:05PMChina Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split (PR Newswire) -7.04% -41.44%
Dec-18-24 08:30AMChina Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville (PR Newswire) -9.78%
Dec-13-24 08:00AMChina Pharma Announces the Entry of "At-The-Market" Equity Offering (PR Newswire)
Aug-19-24 08:00AMChina Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 (PR Newswire)
Feb-23-24 04:05PMChina Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split (PR Newswire) -8.07%
Nov-29-23 08:00AMChina Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device (PR Newswire) +30.16%
Aug-23-23 07:34PMIs China Pharma Holding (CPHI) A Hidden Gem or A Value Trap? (GuruFocus.com) -16.89% -6.33%
Aug-09-23 08:30AMChina Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs (PR Newswire)
Feb-24-23 04:05PMChina Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split (PR Newswire) -17.24%

Key figures

Revenue, TTM	3.91
Net income, TTM	-4.47
EPS diluted, TTM	-0.42
EBIT, TTM	-4.38
Free cash flow, TTM	-0.17
Gross margin	-47.35%
Operating margin	-111.84%
Net margin	-114.33%
Market cap	23.37
P/E	-
Sales Y/Y, TTM	-10.97%

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
No quarterly earnings.

Period

Reported

EPS act

EPS est

EPS rep

Sales act

Sales est

Analysts

No quarterly earnings.

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
2010FY	270	258.34	270	74.39	73.84
2012FY	55.000	-	55.000	54.51	-

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
No estimate revisions.

Period

Type

Date

Estimates

Down

Mean

Low

High

No estimate revisions.

Estimate history

Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
EPS, annual	-220	-123.34	-237.52	-32.86	-36.845	-37.785	-9.1	-2.712	-0.743	-0.4249
EPS, quarterly	-0.892	-0.646	-0.46	-0.241	-0.162	-0.168	-0.176	-0.045	-0.036
Period	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Sales, annual	13.212	12.331	10.924	10.866	9.642	8.104	7.011	4.529	4.144	3.91
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Sales, quarterly	0.925	1.1	1.134	1.136	1.026	0.756	1.226	0.984	0.948
Period	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Shares, annual	0.087	0.087	0.087	0.091	0.095	0.15	1.063	3.262	15.522	40.522
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025	MRQ
Shares, quarterly	1.716	1.786	3.262	3.262	3.262	5.022	15.522	40.522	40.522
Period	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Total Revenue	3.91	4.14	4.53	7.01	8.10	9.64	10.87	10.92	12.33
Cost of Goods Sold Incl. D&A	5.77	5.13	6.96	7.52	8.63	9.33	8.95	9.50	10.47
Gross Profit	-1.85	-0.98	-2.43	-0.50	-0.53	0.31	1.92	1.42	1.86
Selling, General and Administrative Excl. Other	2.52	2.26	2.16	2.25	3.02	3.17	4.50	4.82	5.83
Research and Development	0.33	0.28	0.28	0.24	0.19	0.32	0.38	0.23	0.17
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-4.38	-3.24	-4.59	-2.75	-3.55	-2.86	-2.58	-3.39	-3.97
Interest Expense	0.10	0.10	0.15	0.33	0.43	0.54	0.29	0.32	0.45
Unusual Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	17.02	6.48
Net Income Before Taxes	-4.48	-3.19	-4.74	-3.08	-3.97	-3.40	-2.87	-20.70	-10.86
Income Taxes	-0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.11
Consolidated Net Income	-4.47	-3.19	-4.74	-3.08	-3.97	-3.40	-2.87	-20.70	-10.75
Net Income From Continuing Operations	-4.47	-3.19	-4.74	-3.08	-3.97	-3.40	-2.87	-20.70	-10.75
Net Income	-4.47	-3.19	-4.74	-3.08	-3.97	-3.40	-2.87	-20.70	-10.75
EPS (Recurring)	-0.11	-0.74	-2.71	-9.10	-37.79	-36.85	-32.86	-100.87	-71.30
EPS (Basic, Before Extraordinaries)	-0.42	-0.74	-2.71	-9.10	-37.78	-36.84	-32.86	-237.52	-123.34
EPS (Diluted)	-0.42	-0.74	-2.71	-9.10	-37.78	-36.84	-32.86	-237.52	-123.34
EBITDA	-1.44	-1.66	-1.91	0.00	-0.85	0.23	0.10	-0.46	-0.71
Non-Operating Income (Expense)	0.00	0.15	0.01	0.01	0.01	0.00	0.01	0.03	0.04
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	-	-	-	0.00	0.04	0.02	-	-	-
Price To Sales Ratio	6.83	1.25	0.90	0.29	0.62	2.31	1.79	0.94	0.91
Gross Margin	-47.35	-23.73	-53.72	-7.20	-6.55	3.23	17.64	13.04	15.08
Operating Margin	-111.84	-78.16	-101.32	-39.25	-43.79	-29.67	-23.73	-31.06	-32.18
Net Margin	-114.33	-76.91	-104.58	-43.91	-49.02	-35.26	-26.38	-189.51	-87.18
Shares Outstanding	40.52	15.52	3.26	1.06	0.15	0.09	0.09	0.09	0.09
Market Capitalization	23.37	23.37	44.76	199.36	2,476.26	11,423.05	9,713.98	5,159.82	5,608.69

Income statement, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3
Total Revenue	0.95	0.98	1.23	0.76	1.03	1.14	1.13	1.10
Cost of Goods Sold Incl. D&A	1.82	1.52	1.41	1.01	1.27	1.43	1.43	1.72
Gross Profit	-0.87	-0.54	-0.19	-0.26	-0.24	-0.29	-0.30	-0.62
Selling, General and Administrative Excl. Other	0.56	0.58	1.01	0.37	0.41	0.46	0.90	0.46
Research and Development	0.02	0.08	0.19	0.04	0.02	0.03	0.00	0.09
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-1.43	-1.12	-1.20	-0.63	-0.65	-0.76	-1.20	-1.09
Interest Expense	0.03	0.03	0.02	0.02	0.03	0.03	0.03	0.03
Unusual Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income Before Taxes	-1.46	-1.14	-1.22	-0.65	-0.53	-0.79	-1.22	-1.12
Income Taxes	0.00	0.00	0.00	-0.00	0.00	0.00	0.00	0.00
Consolidated Net Income	-1.46	-1.14	-1.22	-0.65	-0.53	-0.79	-1.22	-1.12
Net Income From Continuing Operations	-1.46	-1.14	-1.22	-0.65	-0.53	-0.79	-1.22	-1.12
Net Income	-1.46	-1.14	-1.22	-0.65	-0.53	-0.79	-1.22	-1.12
EPS (Recurring)	-0.04	-0.04	-0.18	-0.17	-0.16	-0.24	-0.46	-0.65
EPS (Basic, Before Extraordinaries)	-0.04	-0.04	-0.18	-0.17	-0.16	-0.24	-0.46	-0.65
EPS (Diluted)	-0.04	-0.04	-0.18	-0.17	-0.16	-0.24	-0.46	-0.65
EBITDA	-0.33	-0.14	-0.70	-0.27	-0.33	-0.43	-0.75	-0.39
Non-Operating Income (Expense)	0.00	0.00	0.00	0.00	0.15	0.00	0.00	0.00
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price To Sales Ratio	6.83	3.91	2.03	1.86	1.33	2.00	1.37	0.74
Gross Margin	-91.52	-54.88	-15.32	-34.07	-23.82	-25.85	-26.54	-56.76
Operating Margin	-150.98	-113.60	-97.90	-83.06	-63.57	-66.76	-105.47	-98.65
Net Margin	-153.76	-116.23	-99.68	-86.15	-51.51	-69.13	-107.98	-101.61
Shares Outstanding	40.52	40.52	15.52	5.02	3.26	3.26	3.26	1.79
Market Capitalization	23.37	3.06	6.08	6.36	5.84	50.66	44.76	40.56

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY	2017FY
Cash & Short Term Investments	0.35	0.65	1.49	2.04	4.95	1.01	1.23	2.48	2.78
Short Term Receivables	0.29	0.26	0.66	0.45	0.74	0.53	0.68	1.09	2.46
Inventories	1.63	2.28	3.73	3.39	3.34	3.71	3.59	5.06	6.87
Other Current Assets	0.08	0.08	0.11	0.08	0.06	0.07	0.08	0.12	0.19
Total Current Assets	2.35	3.27	6.00	5.96	9.09	5.32	5.58	8.75	12.29
Net Property, Plant & Equipment	4.57	4.92	7.22	10.01	13.41	15.61	16.45	19.29	23.54
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Note Receivable	0.18	0.18	-	-	-	-	-	-	-
Intangible Assets	24.08	6.70	3.26	1.81	0.15	0.18	0.21	17.34	24.12
Other Assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	31.18	15.07	16.47	17.78	22.65	21.12	22.24	45.38	59.95
Short Term Debt Incl. Current Port. of LT Debt	3.48	2.20	3.18	8.76	7.19	6.52	4.42	5.09	4.37
Accounts Payable	0.89	0.23	0.97	0.67	0.93	1.23	1.37	1.06	1.14
Other Current Liabilities	3.03	2.59	2.67	3.32	2.39	3.65	4.26	3.90	3.72
Total Current Liabilities	7.40	5.02	6.82	12.74	10.51	11.40	10.05	10.05	9.23
Long Term Debt	0.11	1.39	1.45	0.00	5.29	0.90	2.20	4.36	6.92
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liabilities	0.75	0.73	0.74	0.75	0.82	0.81	0.75	0.76	0.74
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	8.26	7.14	9.01	13.49	16.63	13.11	13.00	15.18	16.88
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	22.92	7.93	7.45	4.29	6.02	8.00	9.24	30.20	43.07
Total Shareholders Equity	22.92	7.93	7.45	4.29	6.02	8.00	9.24	30.20	43.07
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	22.92	7.93	7.45	4.29	6.02	8.00	9.24	30.20	43.07
Total Liabilities & Stockholders Equity	31.18	15.07	16.47	17.78	22.65	21.12	22.24	45.38	59.95
Book Value Per Share	1.48	2.43	7.02	28.63	63.56	87.81	105.99	346.48	494.17
Tangible Book Value Per Share	-0.07	0.38	3.95	16.57	62.00	85.81	103.63	147.58	217.41
Full-Time Employees	221	231	239	234	246	248	242	252	276
Price to Book Ratio	0.61	6.36	5.69	17.07	37.96	25.38	11.17	3.71	1.34
Return on Assets	-13.78	-30.04	-17.98	-19.65	-15.53	-13.23	-61.24	-20.41	-27.84
Return on Equity	-20.67	-61.58	-52.43	-77.08	-48.49	-33.25	-104.99	-29.34	-37.81
Return on Invested Capital	-13.84	-50.82	-34.57	-92.61	-30.05	-32.18	-181.02	-31.10	-38.56
Quick Ratio	0.10	0.20	0.33	0.20	0.55	0.14	0.20	0.37	0.59
Current Ratio	0.32	0.65	0.88	0.47	0.86	0.47	0.56	0.87	1.33

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Net Income	-4.47	-3.19	-4.74	-3.08	-3.97	-3.40	-2.87	-20.70	-10.75
Depreciation	3.05	1.58	2.68	2.75	2.70	3.09	2.68	2.93	3.26
Other Funds (Non Cash)	-13.53	-13.11	0.46	0.03	-0.02	0.01	0.12	17.27	8.04
Funds from Operations	-14.95	-14.72	-1.60	-0.30	-1.29	-0.30	-0.07	-0.50	0.61
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	14.78	14.87	1.19	-0.40	0.88	0.05	0.14	1.11	0.64
Income Taxes Payable	-	-	-	-	-	-	-	0.01	-0.15
Cash from Operating Activities	-0.17	0.15	-0.41	-0.70	-0.41	-0.25	0.07	0.61	1.26
Capital Expenditures	-0.05	-0.14	-0.29	-0.01	-0.40	-0.44	-0.87	-0.14	-0.05
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Purchase or Sale of Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	-0.05	-0.14	-0.29	-0.01	-0.40	-0.44	-0.87	-0.14	-0.05
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Proceedsfrom Stock Options	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	-0.15	-0.29	-0.03	0.07	-1.77	4.60	0.51	-1.73	-1.98
Change in Long Term Debt	-0.24	-0.56	-0.06	0.04	-1.58	3.98	0.61	-2.17	-1.98
Issuance of Long Term Debt	0.00	0.70	0.49	1.53	0.56	8.83	2.86	0.00	0.29
Reduction of Long Term Debt	-0.24	-1.26	-0.55	-1.49	-2.14	-4.85	-2.25	-2.17	-2.26
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Financing Activities	-0.15	-0.29	-0.03	0.07	-1.77	4.60	0.51	-1.73	-1.98
Exchange Rate Effect	0.05	0.00	-0.07	0.03	-0.25	-0.01	0.06	-0.02	-0.07
Net Change in Cash	-0.32	-0.28	-0.80	-0.61	-2.83	3.90	-0.23	-1.28	-0.84
Free Cash Flow	-0.17	0.09	-0.44	-0.71	-0.81	-0.69	-0.80	0.47	1.21
Preferred Dividends (Cash Flow)	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Free Cash Flow	-	58.41	-	-	-	-	-	21.85	9.30
Deferred Taxes & Investment Tax Credit	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1
Cash & Short Term Investments	0.31	0.17	0.35	0.29	0.63	0.41
Short Term Receivables	0.25	0.26	0.29	0.29	0.32	0.37
Inventories	1.36	1.50	1.63	1.67	1.68	1.99
Other Current Assets	0.09	0.07	0.08	0.08	0.07	0.08
Total Current Assets	2.01	2.00	2.35	2.33	2.70	2.85
Net Property, Plant & Equipment	4.37	4.47	4.57	4.70	4.63	4.80
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00
Intangible Assets	38.34	38.67	24.08	8.78	6.44	6.57
Other Assets	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	44.89	45.32	31.18	15.98	13.95	14.40
Short Term Debt Incl. Current Port. of LT Debt	3.83	3.47	3.48	3.44	2.11	2.11
Accounts Payable	0.73	0.84	0.89	0.59	0.53	0.55
Other Current Liabilities	3.12	2.96	3.03	2.59	2.61	2.46
Total Current Liabilities	7.68	7.27	7.40	6.62	5.25	5.12
Long Term Debt	0.08	0.09	0.11	0.13	1.32	1.39
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liabilities	0.77	0.76	0.75	0.74	0.73	0.73
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	8.53	8.12	8.26	7.49	7.30	7.25
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	36.36	37.20	22.92	8.49	6.64	7.15
Total Shareholders Equity	36.36	37.20	22.92	8.49	6.64	7.15
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	36.36	37.20	22.92	8.49	6.64	7.15
Total Liabilities & Stockholders Equity	44.89	45.32	31.18	15.98	13.95	14.40
Book Value Per Share	0.90	0.92	1.48	1.69	2.04	2.19
Tangible Book Value Per Share	-0.05	-0.04	-0.07	-0.06	0.06	0.18
Full-Time Employees	-	-	221	-	-	-
Price to Book Ratio	0.61	0.66	0.72	0.96	0.82	10.83
Return on Assets	-15.21	-11.87	-13.78	-21.66	-25.92	-29.86
Return on Equity	-20.81	-15.99	-20.67	-42.47	-52.05	-59.14
Return on Invested Capital	-4.00	-3.07	-5.31	-7.56	-6.64	-9.20
Quick Ratio	0.08	0.07	0.10	0.10	0.19	0.17
Current Ratio	0.26	0.28	0.32	0.35	0.51	0.56

Cash flow, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1
Net Income	-1.46	-1.14	-1.22	-0.65	-0.53	-0.79
Depreciation	1.14	0.98	0.57	0.36	0.32	0.33
Other Funds (Non Cash)	0.01	-0.00	-13.65	0.11	0.21	0.21
Funds from Operations	-0.31	-0.16	-14.30	-0.19	0.00	-0.24
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	0.27	0.11	14.45	-0.05	0.29	0.19
Cash from Operating Activities	-0.03	-0.06	0.15	-0.24	0.29	-0.06
Capital Expenditures	0.00	0.00	-0.01	-0.04	-0.01	-0.08
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	0.00	0.00	-0.01	-0.04	-0.01	-0.08
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	0.00	0.00	0.00	0.00	0.00	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Proceedsfrom Stock Options	0.00	0.00	0.00	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	0.12	-0.08	-0.07	-0.12	-0.03	-0.07
Change in Long Term Debt	-0.00	-0.08	-0.08	-0.08	-0.32	-0.08
Issuance of Long Term Debt	0.00	0.00	0.70	-0.70	0.70	0.00
Reduction of Long Term Debt	-0.00	-0.08	-0.78	0.62	-1.02	-0.08
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Financing Activities	0.12	-0.08	-0.07	-0.12	-0.03	-0.07
Exchange Rate Effect	0.05	-0.04	0.00	0.04	-0.04	-0.01
Net Change in Cash	0.14	-0.18	0.08	-0.36	0.21	-0.21
Free Cash Flow	-0.03	-0.06	0.15	-0.24	0.29	-0.12
Price to Free Cash Flow	-	104.25	94.47	48.33	16.39	-

Revenue breakdown

China	2024: 4.53M 2025: 4.14M
Total Pharmaceutical Preparations revenue	2024: 4.53M 2025: 4.14M

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	0.22%	0.1M	40.3M	1.87M
2026-10-15	0.49%	0.2M	40.3M	3.98M
2026-09-30	0.15%	0.1M	40.3M	4.45M
2026-09-15	0.45%	0.2M	40.3M	4.46M
2026-08-31	0.49%	0.2M	40.3M	4.39M
2026-08-14	1.55%	0.6M	40.3M	4.43M
2026-07-31	0.29%	0.1M	40.2M	4.37M
2026-07-15	1.09%	0.4M	37.8M	2.19M
2026-06-30	0.06%	0.0M	37.8M	283.56K
2026-06-15	0.09%	0.0M	37.8M	278.57K
2026-05-29	0.16%	0.1M	37.8M	280.55K
2026-05-15	0.32%	0.1M	37.8M	260.76K
2026-04-30	0.04%	0.0M	18.9M	46.18K
2026-04-15	0.04%	0.0M	18.9M	43.33K
2026-03-31	0.06%	0.0M	18.9M	50.40K
2026-03-13	0.39%	0.0M	2.3M	47.66K
2026-02-27	0.65%	0.0M	2.3M	56.89K
2026-02-13	1.24%	0.0M	2.3M	55.88K
2026-01-30	1.00%	0.0M	2.3M	32.96K
2026-01-15	1.11%	0.0M	2.3M	32.06K

Option chain

expiry 2026-11-11

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-11-10	DEF 14A	Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934	2026-12-22	SEC
2026-10-30	PRE 14A	Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934	2026-10-30	SEC
2026-08-14	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-06-30	SEC
2026-07-23	424B5			SEC
2026-07-22	8-K	Current report	2026-07-22	SEC
2026-05-15	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-03-31	SEC
2026-04-01	10-K	Annual report pursuant to Section 13 or 15(d)	2025-12-31	SEC
2026-04-01	NT 10-K		2025-12-31	SEC
2026-03-03	8-K	Current report	2026-02-26	SEC
2026-02-10	8-K	Current report	2026-02-05	SEC
2026-01-06	8-K	Current report	2025-12-30	SEC
2025-12-23	8-K	Current report	2025-12-22	SEC
2025-12-10	8-K	Current report	2025-12-04	SEC
2025-11-14	DEF 14A	Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934	2025-12-30	SEC
2025-11-12	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2025-09-30	SEC
2025-11-04	PRE 14A	Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934	2025-11-04	SEC
2025-08-14	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2025-06-30	SEC
2025-05-14	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2025-03-31	SEC
2025-04-04	8-K	Current report	2025-04-04	SEC
2025-03-31	10-K	Annual report pursuant to Section 13 or 15(d)	2024-12-31	SEC
2024-12-26	8-K	Current report	2024-12-23	SEC
2024-12-26	8-K	Current report	2024-12-22	SEC
2024-12-13	8-K	Current report	2024-12-12	SEC
2024-12-13	424B5			SEC
2024-11-13	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2024-09-30	SEC
2024-11-12	DEF 14A	Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934	2024-12-22	SEC
2024-11-01	PRE 14A	Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934	2024-11-01	SEC
2024-08-14	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2024-06-30	SEC
2024-05-30	8-K	Current report	2024-05-23	SEC
2024-05-15	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2024-03-31	SEC

Insider activity by month

Month	Bought	Buys	Sold	Sells
2026-11	0	0	0	0
2026-10	0	0	0	0
2026-09	0	0	0	0
2026-08	0	0	0	0
2026-07	0	0	0	0
2026-06	0	0	0	0
2026-05	0	0	0	0
2026-04	0	0	0	0
2026-03	0	0	0	0
2026-02	0	0	0	0
2026-01	0	0	0	0
2025-12	0	0	0	0
2025-11	0	0	0	0

Institutional holders

Manager	% owned
CITADEL ADVISORS LLC	0.31%
TWO SIGMA SECURITIES, LLC	0.09%
StoneX Group Inc.	0.04%
RENAISSANCE TECHNOLOGIES LLC	0.04%
JANE STREET GROUP, LLC	0.03%
Ground Swell Capital, LLC	0.03%
UBS Group AG	0.02%
CITIGROUP INC	0.01%
EFG International AG	0.00%
DANSKE BANK A/S	0.00%

Funds

Fund	% owned
-

Fund

% owned

OakChart. CPHI. Cached 15 minutes.

Some panels did not load: insider.